abstract |
Administering thereto-upfront loading of a bisphosphonate agent can be used to treat primary and secondary osteoporosis, other metabolic bone diseases, alleviation of bone pain, transplant and drug-induced bone loss, Paget's disease of bone, loosening of prosthesis, or metastatic bone diseases in mammals, preferably a human female or a male. A bisphosphonate drug can be administered as a loading dose upfront. Bisphosphonates can be administered by themselves or combined with, one or more other medications acting on bone, such as HRT, selective estrogen receptor modulating drug, calcitonin, parathyroid hormone, fluoride, androgen, sex-steroid hormone analogues, nitroglycerin growth factors and their analogs, peptides and proteins and their analogues, or any other novel therapeutic agents. n This new regimen of administration of an anti-osteoporosis drug (e.g., a bisphosphonate) by itself, or in combination with other medications, can be used in mammals, preferably human (in women and men) for prevention and treatment of osteoporosis (e.g., postmenopausal, glucocorticoid- or drug-induced osteoporosis and osteoporosis in men, etc.) and other metabolic bone disorders, metastatic bone disease, transplant bone disease, Paget's disease, and prevention and treatment of loosening of prosthesis. Disclosed are methods for rapid inhibition of bone resorption in mammals while obtaining a rapid reduction of bone turnover and biomarkers, rapid increase of bone mineral density, and rapid reduction of fractures. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein. |